DJIA 16,408.54 -16.31 -0.10%
NASDAQ 4,095.52 0.00 0.00%
S&P 500 1,864.85 2.54 0.14%
market minute promo

10.15 -0.45 (-4.25%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

INFI $10.15 -4.25%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $10.60
Previous Close $10.60
Daily Range $10.11 - $10.78
52-Week Range $8.91 - $44.50
Market Cap $490.1M
P/E Ratio -3.84
Dividend (Yield) $0.00 (0.0%)
Volume 602,291
Average Daily Volume 688,200
Current FY EPS -$2.98

Sector

Healthcare

Industry

Drugs

Infinity Pharmaceuticals, Inc. (INFI) Description

The Company's mission is to discover, develop, and deliver to patients medicines for the treatment of cancer and related conditions. Website: http://www.infi.com/

News & Commentary Rss Feed

Infinity Pharmaceuticals Enters Oversold Territory (INFI)

Commit To Purchase Infinity Pharmaceuticals At $10, Earn 13.5% Annualized Using Options

Infinity Pharma Rises on Narrower-than-Expected Loss - Analyst Blog

Infinity Pharmaceuticals (INFI) Jumps: Stock Adds 15.5% in Session - Tale of the Tape

Why InterMune, Zulily, and Infinity Pharmaceuticals Are Today's 3 Best Stocks

Economic data pushes the S&P 500 marginally lower as InterMune, Zulily, and Infinity Pharmaceuticals all exploded higher.

Why Infinity Pharmaceuticals Inc. Shares Jumped

Shares of Infinity Pharmaceuticals jump by double-digits after reporting its fourth-quarter earnings results. Find out why investors would be wise to overlook the headline number and focus on this figure instead.

Infinity Pharmaceuticals' CEO Discusses Q4 2013 Results - Earnings Call Transcript

The Hidden Gems in Gilead Sciences' Pipeline

Gilead investors should look beyond the company’s antiviral portfolio and take a closer look at these hidden gems in its pipeline, which could shape the company’s long-term future.

The Billion-Dollar Biotech Club: Speculation Trumped Risk

Synta Pharmaceuticals: 4 Key Investing Takeaways From 2013

Let’s take a look at 4 key investing takeaways from Synta’s volatile year, and how larger companies, like Infinity Pharmaceuticals, Roche, and GlaxoSmithKline, fit into the company’s growth prospects for 2014.

See More INFI News...

INFI's Top Competitors

INFI $10.15 (-4.25%)
Current stock: INFI
AMGN $115.46 (-0.07%)
Current stock: AMGN
GILD $70.00 (1.04%)
Current stock: GILD
BIIB $290.54 (-0.32%)
Current stock: BIIB